COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that the FDA has approved Combivent Respimat (ipratropium bromide and ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced a voluntary recall of over 350,000 Combivent Respimat (ipratropium ...
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday. BI Pharmaceuticals announced the launch of ...
Two asthma inhalers are being phased out, the Food and Drug Administration announced at the end of May. The Combivent Inhalation Aerosol and the Maxair Autohaler both contain chlorofluorocarbons (CFCs ...
Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has been hit with a prospective class action lawsuit that alleges its Combivent asthma inhaler provides far less than the number of ...